BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22383295)

  • 1. Impact of expression system on the function of the C6.5 diabody PET radiotracer.
    Miller J; Doss M; McQuillen R; Shaller CC; Tolner B; Yu JQ; Chester K; Robinson MK
    Tumour Biol; 2012 Jun; 33(3):617-27. PubMed ID: 22383295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.
    Reddy S; Shaller CC; Doss M; Shchaveleva I; Marks JD; Yu JQ; Robinson MK
    Clin Cancer Res; 2011 Mar; 17(6):1509-20. PubMed ID: 21177408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.
    Robinson MK; Doss M; Shaller C; Narayanan D; Marks JD; Adler LP; González Trotter DE; Adams GP
    Cancer Res; 2005 Feb; 65(4):1471-8. PubMed ID: 15735035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner.
    González Trotter DE; Manjeshwar RM; Doss M; Shaller C; Robinson MK; Tandon R; Adams GP; Adler LP
    J Nucl Med; 2004 Jul; 45(7):1237-44. PubMed ID: 15235072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
    Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
    J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
    Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
    J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.
    Robinson MK; Shaller C; Garmestani K; Plascjak PS; Hodge KM; Yuan QA; Marks JD; Waldmann TA; Brechbiel MW; Adams GP
    Clin Cancer Res; 2008 Feb; 14(3):875-82. PubMed ID: 18245551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging.
    Olafsen T; Sirk SJ; Olma S; Shen CK; Wu AM
    Tumour Biol; 2012 Jun; 33(3):669-77. PubMed ID: 22392499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.
    Vaneycken I; Devoogdt N; Van Gassen N; Vincke C; Xavier C; Wernery U; Muyldermans S; Lahoutte T; Caveliers V
    FASEB J; 2011 Jul; 25(7):2433-46. PubMed ID: 21478264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First clinical study of a pegylated diabody
    Scott AM; Akhurst T; Lee FT; Ciprotti M; Davis ID; Weickhardt AJ; Gan HK; Hicks RJ; Lee ST; Kocovski P; Guo N; Oh M; Mileshkin L; Williams S; Murphy D; Pathmaraj K; O'Keefe GJ; Gong SJ; Pedersen JS; Scott FE; Wheatcroft MP; Hudson PJ
    Theranostics; 2020; 10(25):11404-11415. PubMed ID: 33052222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
    Schneider DW; Heitner T; Alicke B; Light DR; McLean K; Satozawa N; Parry G; Yoo J; Lewis JS; Parry R
    J Nucl Med; 2009 Mar; 50(3):435-43. PubMed ID: 19223400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging.
    Venisnik KM; Olafsen T; Gambhir SS; Wu AM
    Mol Imaging Biol; 2007; 9(5):267-77. PubMed ID: 17577599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.
    Adams GP; Shaller CC; Dadachova E; Simmons HH; Horak EM; Tesfaye A; Klein-Szanto AJ; Marks JD; Brechbiel MW; Weiner LM
    Cancer Res; 2004 Sep; 64(17):6200-6. PubMed ID: 15342405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
    Adams GP; Schier R; McCall AM; Crawford RS; Wolf EJ; Weiner LM; Marks JD
    Br J Cancer; 1998 May; 77(9):1405-12. PubMed ID: 9652755
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.